The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•7 April 2026•

1 min read

Citigroup Lowers Stryker Price Target as RBC Capital Maintains Sell Rating on Pfizer

Key Facts

1Citigroup lowered the price target for Stryker Corp (SYK) from $420 to $385 while maintaining a 'Buy' rating.

2RBC Capital maintained its 'Sell' rating on Pfizer (PFE) with a target price of $25.

Analysts have issued updated ratings and price targets for major players in the healthcare and medical technology sectors, specifically focusing on Stryker and Pfizer. Citigroup lowered its price target for Stryker Corp (SYK) to $385 from $420, while maintaining a "Buy" rating on the stock. Meanwhile, RBC Capital reiterated its "Sell" rating on Pfizer (PFE) with a target price of $25, reflecting a continued bearish outlook. These adjustments come as analysts assess company-specific performance and broader market conditions ahead of the Q1 2026 earnings season. While the target cut for Stryker suggests a more cautious valuation, the retained "Buy" rating indicates underlying confidence in the company's growth. Conversely, Pfizer continues to face skepticism from analysts, as evidenced by the maintained underperform rating.

Version History

1 additional source confirmed this story